April 14, 2017
Espoo, Finland. 11.4.2017
Contract research organization StatFinn reports strong growth in financial year 2016. StatFinn merged its clinical data analytics business with Real-World Evidence company EPID Research. The pro forma financial statement shows total sales of €4,7 million with a growth rate of 49,2 percent. Earnings before taxes doubled to €0,7 million.
“With the merger, we can offer a full range of services to our clients from Phase I to Phase IV and beyond. We expect our strong global growth to continue in 2017,” says Eero Mertano, CEO of StatFinn and EPID Research.
StatFinn employs over 70 experts with presence in five countries: Estonia, Finland, Poland, Sweden and Switzerland.
Eero Mertano, CEO, StatFinn, email@example.com, +358 40 769 6275
StatFinn and EPID Research offer a full range of services to their clients in clinical data analytics and Real-World Evidence from Phase I to Phase IV and beyond. The combined company employs over 70 experts with presence in five countries: Estonia, Finland, Poland, Sweden and Switzerland. www.statfinn.fi www.epidresearch.com